Dr. Sajjan Rajpurohit is one of India's most revered Medical Oncologists with over two decades of clinical experience in managing complex solid malignancies and hematologic neoplasms. Trained at prestigious premier institutes including AIIMS New Delhi and certified by the European Society for Medical Oncology (ESMO), Dr. Rajpurohit has pioneered the application of Next-Generation Genomic Sequencing (NGS) and checkpoint immunotherapy in refractory lung, gastrointestinal, and breast cancers.
With over 22 years in tertiary oncology hospitals, Dr. Sajjan Rajpurohit routinely coordinates multidisciplinary cancer care across precision surgical resections, genomic-driven targeted treatments, and comprehensive daycare chemotherapy regimens.
Individualized oral and IV TKI protocols guided by liquid biopsy and NGS panel assays.
Systemic immunotherapy infusions under monitored clinical daycare with strict immune-related AE management.
High-precision outpatient elastomeric pump infusions minimizing hospital admissions.
Comprehensive multi-specialist review of biopsy slides, PET-CT scans, and personalized clinical roadmaps.
| Hospital & Clinic Centre | Consultation Days | OPD Timings | Room / Department |
|---|---|---|---|
| Max Super Speciality Hospital, Saket | Mon, Wed, Fri | 10:00 AM – 02:00 PM | OPD Block B, Room 204 |
| Max Super Speciality Hospital, Shalimar Bagh | Tue, Thu, Sat | 03:00 PM – 07:00 PM | Cancer Centre, Room 108 |
| MedSuggest Tele-Oncology Digital Clinic | Mon – Sat | 07:30 PM – 09:30 PM | Verified HD Video Suite |
"Dr. Sajjan explained the NGS report in simple Hindi and started targeted therapy without harsh IV chemo. My father’s breathlessness decreased within 3 weeks. A truly compassionate doctor."
"His supportive care protocols made chemotherapy manageable with zero vomiting episodes. The video consultation option on MedSuggest was seamless for follow-up blood count reviews."
"Got a second opinion from Dr. Rajpurohit when another hospital suggested immediate radical surgery. He recommended 4 cycles of neoadjuvant immunotherapy first, which shrunk the tumor by 60%!"
